CompletedNCT07549581
A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode
Medication studyAges 18–55United StatesDepression
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- Los AlamitosSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: November 7, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 43
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT07549581
- Official title
Show the full official title
A Phase 1b, Randomized, Double-blind, Placebo-controlled Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of SEP-380135 in Adults With Schizophrenia or With a Major Depressive Episode Associated With Bipolar I or II Disorder or Major Depressive Disorder
Get this study by email
Recruitment & locations
CompletedLos Alamitos
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including SEP-380135 and Placebo.
Who was this study for?
Listed age limits: 18 years to 55 years.
